ORIC Pharmaceuticals presented preclinical and patient data at ESMO Congress 2026 showing that rinzimetostat, a PRC2 inhibitor targeting EED, may improve prostate cancer treatment by increasing tumor sensitivity to androgen receptor (AR) inhibitors. Unlike EZH2 inhibitors, rinzimetostat maintained effectiveness against resistance mutations and showed no tumorigenesis in animal studies. The drug reinforced AR dependence and limited tumor adaptability in preclinical models and patient samples, supporting its ongoing Phase 3 Himalayas-1 trial. These findings suggest rinzimetostat could offer a best-in-class option for prostate cancer across disease stages.
ORIC Pharmaceuticals' prostate cancer treatment data is presented here with Pluang's health sector market context for readers. As of Oct 23, 2026 14:31 WIB, 63 of 150 priced health-sector US stocks on Pluang rose while 85 fell. Notable movers include HRTX at USD 0.29 with a 14.20% decline, NUWE at USD 0.53 rising 7.63%, and MRVI at USD 7.05 down 6.80%.
Ipsos posted €636.2 million revenue in Q3 2026 with 2.0% organic growth, up from 0.8% in H1, led by strong performances in EMEA, China, and its Citizens business. The company updated its full-year organic growth outlook to 1.2%-1.5%, citing ongoing g...
Ipsos achieved 2.0% organic revenue growth in Q3 2026, up from 0.8% in H1, driven by strong performances in EMEA, China, and citizen-related activities. The company updated its 2026 organic growth target to 1.2%-1.5%, reflecting improved momentum and...
Signify reported third-quarter 2026 results with sales of EUR 1,367 million, a slight decline in comparable sales by 3.4%, but improved adjusted EBITA of EUR 145 million and a margin increase to 10.6%. Net income rose to EUR 88 million and free cash ...
A single cryptocurrency wallet sold 246.25 BTC worth $20.64 million and purchased 8,286 ETH of equal value, indicating a rotation from Bitcoin to Ether rather than new capital entering the market. Over 11 days, the wallet sold 1,917.7 BTC for $159 mi...
Ondine Biomedical's Steriwave antimicrobial treatment reduced surgical-site infections by 51.5% at the University of Ottawa Heart Institute, Canada's largest cardiac center, dropping infection rates from 3.3% to 1.6% in 2,172 procedures. Patient comp...
